Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421811 · ClinicalTrials.gov registry record · Phase 1
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
A Phase 1 study of Neoplasms, sponsored by Adherex Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 7
- Study locations
NCT00421811 is a Phase 1 study of Neoplasms that has completed, run by Adherex Technologies. The registered enrollment target is 56 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00421811, a Phase 1 study of Neoplasms, has completed, sponsored by Adherex Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 7
- Study locations
Study Summary
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma.
Conditions Studied
Interventions
- DRUG melphalan
- DRUG ADH-1
Study Locations (7)
Florida
- University of Florida College of Medicine - Gainesville
- H. Lee Moffitt Cancer Center - Tampa
Colorado
- University of Colorado, Denver - Aurora
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Lehigh Valley Hospital - Allentown
Texas
- MD Anderson Cancer Center - Houston
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421811
The ClinicalTrials.gov registry entry for NCT00421811 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Adherex Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which melphalan is the first listed.
NCT00421811 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Florida, Colorado, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00421811 about?
NCT00421811 is a clinical study titled "A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan". N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with ...
What is the current status of trial NCT00421811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-04. Estimated completion is 2009-03.
What conditions does trial NCT00421811 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00421811?
The interventions under investigation include: melphalan (DRUG), ADH-1 (DRUG).
Who is sponsoring clinical trial NCT00421811?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421811 being conducted?
This trial has 7 study locations across Colorado, Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.